Evidence map›Paper›PMID 39886207›Full record

ArticleJTO clinical and research reports2024

Combined RET and MEK Inhibition as a Treatment for

Jacobi B Hines, Benjamin C Bowar, Margaret Colleton, Lydia Chelala, Peng Wang, Angad A Chadha, Jeremy Segal, Christine M Bestvina

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jacobi B HinesDepartment of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.
Benjamin C BowarDepartment of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.
Margaret ColletonDepartment of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.
Lydia ChelalaDepartment of Radiology, University of Chicago Medical Center, Chicago, Illinois.
Peng WangDepartment of Pathology, University of Chicago Medical Center, Chicago, Illinois.
Angad A ChadhaDepartment of Medicine, Section of Dermatology, University of Chicago Medical Center, Chicago, Illinois.
Jeremy SegalDepartment of Pathology, University of Chicago Medical Center, Chicago, Illinois.
Christine M BestvinaDepartment of Medicine, Section of Hematology and Oncology, University of Chicago Medical Center, Chicago, Illinois.

Funding

CLINICAL THERAPEUTICST32GM007019 · NIGMS · UNIVERSITY OF CHICAGO · PI Peter Hugh O'Donnell, MARK J RATAIN · 1985 to 2026
$8.7M
NIGMS NIH HHS T32 GM007019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic drug resistanceBRAF fusionCase reportMolecular targeted therapyNon–small cell lung cancerRET fusion

Identifiers

PMID39886207
PMCPMC11780364

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.